bluebird bio, Inc. (NASDAQ:BLUE) is scheduled to announce its earnings results after the market closes on Tuesday, August 1st. Analysts expect the company to announce earnings of ($1.66) per share for the quarter.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.76) by $0.08. The business had revenue of $6.83 million for the quarter, compared to analysts’ expectations of $1.51 million. bluebird bio had a negative return on equity of 35.17% and a negative net margin of 2,402.03%. On average, analysts expect bluebird bio to post $-6.73 EPS for the current fiscal year and $-7 EPS for the next fiscal year.
bluebird bio, Inc. (NASDAQ:BLUE) opened at 96.70 on Friday. The firm has a 50-day moving average price of $103.95 and a 200 day moving average price of $88.30. The stock’s market capitalization is $3.96 billion. bluebird bio, Inc. has a 12 month low of $37.05 and a 12 month high of $123.75.
In other bluebird bio news, insider Jeffrey T. Walsh sold 2,500 shares of the stock in a transaction that occurred on Monday, July 10th. The stock was sold at an average price of $99.89, for a total transaction of $249,725.00. Following the transaction, the insider now owns 29,805 shares in the company, valued at $2,977,221.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Lynch sold 2,000 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $80.00, for a total value of $160,000.00. Following the transaction, the director now owns 3,400 shares in the company, valued at approximately $272,000. The disclosure for this sale can be found here. Insiders have sold 73,245 shares of company stock worth $7,660,998 in the last quarter. 3.90% of the stock is currently owned by company insiders.
Several analysts have weighed in on the company. Sanford C. Bernstein assumed coverage on bluebird bio in a research note on Thursday. They set a “market perform” rating and a $109.00 price target on the stock. Cantor Fitzgerald reiterated a “sell” rating and set a $39.00 price target on shares of bluebird bio in a research note on Monday, July 24th. Zacks Investment Research downgraded bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Cowen and Company reiterated an “outperform” rating on shares of bluebird bio in a research note on Friday, June 9th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $108.00 price target on shares of bluebird bio in a research note on Tuesday, June 6th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $100.54.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.